Pasithea Therapeutics Corp.(KTTA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KTTA Pasithea Therapeutics Corp.

Closed 07-22 16:00:00 EDT

0.4600

+0.0052

+1.14%

盘后0.4600

+0.00000.00%

16:10 EDT

High0.4873	Low0.4550	Vol344.18K
Open0.4578	D1 Closing0.4548	Amplitude7.10%
Mkt Cap15.37M	Tradable Cap4.69M	Total Shares33.41M
T/O159.85K	T/O Rate3.37%	Tradable Shares10.20M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"KTTA","market":"US","secType":"STK","nameCN":"Pasithea Therapeutics Corp.","latestPrice":0.46,"timestamp":1784750400000,"preClose":0.4548,"halted":0,"volume":344183,"hourTrading":{"tag":"盘后","latestPrice":0.46,"preClose":0.46,"latestTime":"16:10 EDT","volume":5,"amount":2.3,"timestamp":1784751004378,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.01143359718557616,"floatShares":10202000,"shares":33414448,"eps":-1.9764,"marketStatus":"Closed","change":0.0052,"latestTime":"07-22 16:00:00 EDT","open":0.4578,"high":0.4873,"low":0.455,"amount":159849,"amplitude":0.07102,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.9764,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1784793600000},"marketStatusCode":5,"adr":0,"listingDate":1628654400000,"exchange":"NASDAQ","adjPreClose":0.4548,"preHourTrading":{"tag":"盘前","latestPrice":0.459,"preClose":0.4548,"latestTime":"08:53 EDT","volume":780,"amount":357.108921,"timestamp":1784724836361,"change":0.0042,"changeRate":0.009235,"amplitude":0.032762},"postHourTrading":{"tag":"盘后","latestPrice":0.46,"preClose":0.46,"latestTime":"16:10 EDT","volume":5,"amount":2.3,"timestamp":1784751004378,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.757324},"requestUrl":"/m/hq/s/KTTA/tweets","defaultTab":"tweets","newsList":[{"id":"2653725209","title":"Pasithea Therapeutics Posts Investor Presentation on Pas-004 MEK Inhibitor Program in NF1 and Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2653725209","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653725209?lang=en_us&edition=fundamental","pubTime":"2026-07-21 23:53","pubTimestamp":1784649216,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics posts investor presentation on PAS-004 MEK inhibitor program in NF1 and solid tumorsPasithea highlighted PAS-004, a next-generation macrocyclic MEK1/2 inhibitor, as its lead prog","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nNDL5d3MQr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653271935","title":"Pasithea Therapeutics Posts Press Release on Pas-004 Data Presentation at ESMO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2653271935","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653271935?lang=en_us&edition=fundamental","pubTime":"2026-07-21 19:03","pubTimestamp":1784631818,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics posts press release on PAS-004 data presentation at ESMO 2026Pasithea posted a new press release on PAS-004 ahead of an ESMO Congress 2026 poster on its Phase 1 dose-escalation s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nNDL4DbvDv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139","KTTAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651113499","title":"Pasithea Publishes Investor Presentation on Pas-004 Macrocyclic MEK Inhibitor Program in NF1 and Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2651113499","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651113499?lang=en_us&edition=fundamental","pubTime":"2026-07-16 05:38","pubTimestamp":1784151510,"startTime":"0","endTime":"0","summary":"Pasithea publishes investor presentation on PAS-004 macrocyclic MEK inhibitor program in NF1 and solid tumorsPasithea outlined clinical development plans for PAS-004, a macrocyclic MEK1/2 inhibitor ta","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDL69F8my:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649998636","title":"Pasithea Therapeutics to Attend B. Riley Securities Mind, Muscle & Vision Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2649998636","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649998636?lang=en_us&edition=fundamental","pubTime":"2026-07-08 19:06","pubTimestamp":1783508813,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics to attend B. Riley Securities Mind, Muscle & Vision SummitPasithea Therapeutics will attend B. Riley Securities’ Mind, Muscle & Vision Summit on July 16, 2026, in Boston.Manageme","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nNDL9Dx4bV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649064975","title":"Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2649064975","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649064975?lang=en_us&edition=fundamental","pubTime":"2026-07-06 15:21","pubTimestamp":1783322486,"startTime":"0","endTime":"0","summary":"June 30 (Reuters) - Pasithea Therapeutics Corp::*ANNOUNCES POSITIVE INTERIM PHASE 1 ADVANCED CANCER STUDY DATA DEMONSTRATING LONG-TERM SAFETY AND TOLERABILITY, AND DURABLE CLINICAL ACTIVITY IN MEK/BRA","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nRSD2YksQL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647583845","title":"Pasithea Therapeutics announces updated data from PAS-004 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2647583845","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647583845?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:15","pubTimestamp":1782818144,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics (KTTA) announced updated interim safety and clinical activity data from its ongoing first-in-human trial evaluating PAS-004 i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pasithea-therapeutics-announces-updated-data-from-pas-004-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pasithea-therapeutics-announces-updated-data-from-pas-004-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647980530","title":"Pasithea Therapeutics Corp - Protocol Amendment Extends Dose Escalation up to 52mg for Pas-4","url":"https://stock-news.laohu8.com/highlight/detail?id=2647980530","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647980530?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:00","pubTimestamp":1782817202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nTUA3JB5CL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647653093","title":"Pasithea Therapeutics Corp - Pas-4 Shows Favorable Safety Profile with Only Grade 1 or 2 Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2647653093","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647653093?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:00","pubTimestamp":1782817202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nTUA3JB5CL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647530933","title":"Pasithea Therapeutics Corp - Initiates Pilot Food Effect Study for Pas-4 Pharmacokinetics","url":"https://stock-news.laohu8.com/highlight/detail?id=2647530933","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647530933?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:00","pubTimestamp":1782817202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nTUA3JB5CL:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647305735","title":"Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-term Safety and Tolerability, and Durable Clinical Activity in Mek/braf-pretreated Patients, Plus Protocol Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2647305735","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647305735?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:00","pubTimestamp":1782817202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nTUA3JB5CL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647530165","title":"Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2647530165","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647530165?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:00","pubTimestamp":1782817200,"startTime":"0","endTime":"0","summary":"--Favorable Safety Profile Supports Long-Term Chronic Dosing: PAS-004 has been well-tolerated, with all treatment-related adverse events (TRAEs) being Grade 1 or 2, no observed cardiac or retinal trea","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/30/3319538/0/en/Pasithea-Therapeutics-Announces-Positive-Interim-Phase-1-Advanced-Cancer-Study-Data-Demonstrating-Long-Term-Safety-and-Tolerability-and-Durable-Clinical-Activity-in-MEK-BRAF-Pretre.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645004895","title":"Major Investor Quietly Boosts Stake in Pasithea Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2645004895","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645004895?lang=en_us&edition=fundamental","pubTime":"2026-06-23 10:06","pubTimestamp":1782180392,"startTime":"0","endTime":"0","summary":"New insider activity at Pasithea Therapeutics Corp ( ($KTTA) ) has taken place on June 22, 2026. Significant shareholder Coastlands Capital LP has ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/major-investor-quietly-boosts-stake-in-pasithea-therapeutics-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/major-investor-quietly-boosts-stake-in-pasithea-therapeutics-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645073688","title":"Coastlands Capital LP buys 100,000 Pasithea Therapeutics shares for $53,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2645073688","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645073688?lang=en_us&edition=fundamental","pubTime":"2026-06-22 22:31","pubTimestamp":1782138691,"startTime":"0","endTime":"0","summary":"Coastlands Capital bought 100,000 Pasithea Therapeutics common shares in an open-market purchase at $0.53 each.Holdings rose to 3,835,035 shares, held indirectly through Coastlands Capital.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 22, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL3Kw9fv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Coastlands Capital LP buys 100,000 Pasithea Therapeutics shares for $53,000","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644766759","title":"Analysts Are Bullish on Top Healthcare Stocks: Pasithea Therapeutics Corp (KTTA), Adaptive Biotechnologies (ADPT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2644766759","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644766759?lang=en_us&edition=fundamental","pubTime":"2026-06-16 23:50","pubTimestamp":1781625010,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Pasithea Therapeutics Corp (KTTA) and Adaptive Biote...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-pasithea-therapeutics-corp-ktta-adaptive-biotechnologies-adpt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-pasithea-therapeutics-corp-ktta-adaptive-biotechnologies-adpt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADPT","KTTA","BK4121","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643669187","title":"Pasithea Therapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2643669187","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643669187?lang=en_us&edition=fundamental","pubTime":"2026-06-16 23:47","pubTimestamp":1781624820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KTTA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 16, 2026 11:47 ET (15:47 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643752785","title":"Pasithea Therapeutics Amends PAS-004 Trial to Add Higher Dose Levels, Extend Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2643752785","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643752785?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:34","pubTimestamp":1781613279,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics  amended the protocol for its phase 1/1b trial of PAS-004 in neurofibromatosis type 1 patients with symptomatic inoperable, incompletely resected or recurrent plexiform neurofibromas, the company said Tuesday.The amended protocol adds higher dose levels of 24 mg and 32 mg, allows evaluation of intermediate doses and extends treatment in the dose-escalation portion of the study to up to 18 months, Pasithea Therapeutics said.The company has completed enrollment and multi-cycle dosing in the 4 mg, 8 mg, 12 mg and 18 mg cohorts and has enrolled patients in the 15 mg and 24 mg cohorts, it said.Pasithea Therapeutics said it remains on track to provide an interim update from the trial in Q4.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643759243","title":"Pasithea Therapeutics expands PAS-004 Phase 1/1b NF1 trial with higher dose cohorts","url":"https://stock-news.laohu8.com/highlight/detail?id=2643759243","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643759243?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:02","pubTimestamp":1781607754,"startTime":"0","endTime":"0","summary":"Pasithea amended its Phase 1/1b trial protocol for PAS-004 in NF1 patients with plexiform neurofibroma, expanding dose escalation.Interim NF1 data were not presented; an update remains scheduled for Q4 2026.Changes aim to broaden dosing experience, extend treatment duration, improve imaging and skin tumor assessments to support dose selection.Enrollment and multi-cycle dosing completed for initial cohorts; 18 patients dosed in Part A, with 24 mg and an intermediate 15 mg cohort enrolled.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL2NM5PG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643759641","title":"Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B Nf1 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2643759641","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643759641?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:00","pubTimestamp":1781607600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nTUA3DZGB1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643759193","title":"Pasithea Therapeutics - Amendments Add 24Mg and 32Mg Dose Levels and Backfilling of Cohorts in Phase 1/1B Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2643759193","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643759193?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:00","pubTimestamp":1781607600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nTUA3DZGB1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643759185","title":"Pasithea Therapeutics - on Track to Release Interim Nf1 Data Update in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2643759185","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643759185?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:00","pubTimestamp":1781607600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nTUA3DZGB1:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pasithea.com","stockEarnings":[{"period":"1week","weight":-0.0562},{"period":"1month","weight":-0.0904},{"period":"3month","weight":-0.3594},{"period":"6month","weight":-0.4995},{"period":"1year","weight":-0.3551},{"period":"ytd","weight":-0.6474}],"compareEarnings":[{"period":"1week","weight":-0.0047},{"period":"1month","weight":0.0021},{"period":"3month","weight":0.0521},{"period":"6month","weight":0.0861},{"period":"1year","weight":0.1901},{"period":"ytd","weight":0.0973}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.182441},{"month":2,"riseRate":0.4,"avgChangeRate":-0.152614},{"month":3,"riseRate":0.4,"avgChangeRate":-0.0152},{"month":4,"riseRate":0.2,"avgChangeRate":0.004803},{"month":5,"riseRate":0.4,"avgChangeRate":-0.176425},{"month":6,"riseRate":0.4,"avgChangeRate":-0.006229},{"month":7,"riseRate":0.8,"avgChangeRate":0.058844},{"month":8,"riseRate":0.5,"avgChangeRate":-0.003687},{"month":9,"riseRate":0.5,"avgChangeRate":-0.003936},{"month":10,"riseRate":0.2,"avgChangeRate":-0.132455},{"month":11,"riseRate":0.4,"avgChangeRate":0.147256},{"month":12,"riseRate":0.4,"avgChangeRate":-0.165941}],"exchange":"NASDAQ","name":"Pasithea Therapeutics Corp.","nameEN":"Pasithea Therapeutics Corp."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pasithea Therapeutics Corp.(KTTA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Pasithea Therapeutics Corp.(KTTA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Pasithea Therapeutics Corp.,KTTA,Pasithea Therapeutics Corp.股票,Pasithea Therapeutics Corp.股票老虎,Pasithea Therapeutics Corp.股票老虎国际,Pasithea Therapeutics Corp.行情,Pasithea Therapeutics Corp.股票行情,Pasithea Therapeutics Corp.股价,Pasithea Therapeutics Corp.股市,Pasithea Therapeutics Corp.股票价格,Pasithea Therapeutics Corp.股票交易,Pasithea Therapeutics Corp.股票购买,Pasithea Therapeutics Corp.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pasithea Therapeutics Corp.(KTTA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Pasithea Therapeutics Corp.(KTTA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction